Director Dumesnil Simon bought 33,333 shares of KTTA at $0.75; holdings increase +1333.3%; 2 other insiders also bought within 14 days.
Dumesnil Simon, a director, purchased 33,333 shares at $0.75 on 2025-11-28, increasing his holdings from 2,500 shares to 35,833 shares—a gain of +1333.3% relative to his pre-transaction position. This transaction co-occurs with a cluster pattern: 2 other insiders also bought within the past 14 days. The context reveals material volatility and fundamental weakness: the stock is -63.2% from its 52-week high of $3.15, though it has recovered +42.6% over the past 30 days and +29.1% over 90 days. Pasithea Therapeutics remains unprofitable, with a net loss of $-3,037,420.00 in its most recent full fiscal year and quarterly revenue of only $218,608.00, while the company carries a market cap of $8,634,549.32. The convergence of multiple insider purchases at depressed valuations within a short window, alongside signs of recent price recovery, warrants examination of whether this reflects deliberate positioning by the board or merely coincidental timing around company developments.